Pulgas

5-HTP is the direct serotonin precursor, and a randomized double-blind placebo-controlled study (Keszthelyi et al., Neurogastroenterol Motil 2015, n=15 IBS patients) found 5-HTP induced significant alterations in serotonergic metabolites and affected visceral pain perception in hypersensitive IBS patients, confirming the role of altered serotonin metabolism in IBS pathophysiology.

A 4-week randomized, double-blind, placebo-controlled trial (European Journal of Nutrition, 2024) studied acacia fiber specifically in constipation-predominant IBS patients. Additional clinical and traditional evidence documents improvement in IBS bowel symptoms including stool regularity and abdominal discomfort. Acacia fiber is recommended as a supplement for IBS by several evidence-based databases.

Activated charcoal has been evaluated in an IBS-specific clinical trial. A published RCT (Hübner and Moser, Adv Ther 2002) assessed charcoal tablets specifically in IBS patients and found significant benefit for abdominal discomfort. Its adsorptive mechanism directly addresses intestinal gas, bloating, and flatulence—core IBS symptoms. It is cited in IBS supplement evidence reviews alongside peppermint oil and psyllium.

Reduced A. muciniphila gut abundance has been documented in IBS patients, and the bacterium's gut barrier-reinforcing properties are mechanistically relevant to IBS pathophysiology, which involves increased gut permeability and visceral hypersensitivity. Pasteurized A. muciniphila improved gut permeability, colonic sensitivity, and behavioral indicators in two mouse IBS models. A human pilot RCT examining pasteurized A. muciniphila in IBS subjects is ongoing.

Aloe vera has been evaluated in several IBS-specific RCTs, with a 2025 umbrella review (Nutr Rev, 175 trials) confirming it improved IBS symptoms alongside peppermint oil and soluble fiber. A 2006 double-blind RCT (Davis et al., Int J Clin Pract) and a randomized crossover study (Hutchings et al., ISRN Gastroenterol 2011) both assessed aloe vera specifically in IBS patients. Mechanisms include anti-inflammatory effects on the gut mucosa and mild laxative activity.

Digestive enzyme blends containing amylase have been investigated in IBS patients. Incomplete carbohydrate digestion contributes to fermentation-driven IBS symptoms; amylase addresses starch substrates within this pathway. Clinical trials of multi-enzyme combinations report modest improvements in bloating, gas, and abdominal pain in IBS populations.

Artichoke leaf extract (ALE) has moderate clinical evidence for functional dyspepsia and IBS, including several RCTs. It exerts prokinetic and anti-inflammatory effects via cynarin and chlorogenic acid. A large observational study (n=279) showed significant IBS symptom improvement with ALE. It is also a component of the Iberogast combination formula studied in IBS trials.

Oryz-Aspergillus enzyme and pancreatin tablets have been studied in a clinical trial for constipation-predominant IBS (IBS-C), assessing improvement in bowel habits and abdominal symptoms based on the brain-gut axis. Separately, mycobiome research has identified Aspergillus abundance patterns as predictive markers in IBS patients. The enzyme product Combizym® has established indication for dyspepsia overlapping functionally with IBS presentations.

Atractylodes macrocephala is a key ingredient in TCM formulas evaluated in systematic reviews and meta-analyses for IBS. Its polysaccharides and volatile oils modulate gut microbiota, intestinal motility, and visceral sensitivity in IBS-relevant preclinical models. Meta-analytic evidence for TCM formulas containing AMR is positive for IBS symptom relief.

A 2022 phase III double-blind RCT in children with IBS (Rome IV) found no significant difference between B. clausii and placebo added to conventional therapy, though the study was underpowered due to unexpectedly high placebo response. An earlier observational study reported B. clausii benefit for IBS-related SIBO. Evidence is currently insufficient to confirm efficacy for IBS.

Bacillus coagulans has demonstrated IBS efficacy in multiple RCTs and meta-analyses. A 90-day RCT of B. coagulans MTCC 5856 (2 billion CFU/day) significantly improved bloating, diarrhea, abdominal pain, and stool frequency in IBS-D versus placebo. A 2025 strain-specific meta-analysis confirmed B. coagulans Unique IS2 and MTCC 5856 in meta-analyses of IBS symptom improvement and quality-of-life outcomes.

Bacillus subtilis is a spore-forming probiotic included in evidence-based IBS probiotic literature. It is cited in clinical probiotic guidance as a soil-based organism with benefits for gut barrier function relevant to IBS. It is included in multi-strain probiotic preparations studied for IBS, with spore-forming properties ensuring GI delivery.

Banana fiber—particularly the soluble pectin and resistant starch in unripe forms—has demonstrated benefits on IBS-related symptoms including constipation, diarrhea, and abdominal discomfort in RCT-level evidence. A 2022 RCT of a resistant starch blend including green banana flour improved multiple GI symptoms relevant to IBS. Evidence for banana as a standalone IBS intervention is limited but the fiber-based mechanism is clinically recognized.

Animal studies and emerging clinical data support berberine from barberry for IBS-related visceral hypersensitivity, acting by normalizing gut microbiota and suppressing spinal microglial activation. A registered clinical trial references berberine for diarrhea-predominant IBS. Traditional use of barberry for diarrheal illness aligns with this application.

The pivotal 4-week DB-RCT (BMC Complementary and Alternative Medicine, 2014) enrolled subjects with GI discomfort profiles overlapping IBS — functional GI intolerance with bloating, altered bowel movements, and abdominal symptoms — and showed significant symptom improvement with 300 mg/day Benegut. The study is specifically cited in reference databases as demonstrating IBS-relevant benefits. Mechanistic data show prokinetic, antispasmodic, and anti-inflammatory activity consistent with IBS pathophysiology.

Berberine has multiple clinical studies demonstrating benefit in IBS, particularly IBS-D. A 2024 observational clinical study (Nutrients, n=146 IBS patients) combining berberine with curcumin found 93.1% experienced symptom improvement or resolution. Berberine reduces gut inflammation, modulates microbiota, and suppresses visceral hypersensitivity via the gut-brain axis. It is among the most pharmacologically studied botanicals for IBS-D.

Beta-glucan's prebiotic fermentation supports microbiome diversity and SCFA production, addressing gut dysbiosis implicated in IBS. Several RCTs have reported reductions in abdominal pain, bloating, and normalized bowel movements in IBS patients. Effectiveness may vary by IBS subtype (constipation-predominant vs. diarrhea-predominant).

Bifidobacterium species have extensive clinical evidence for IBS. A 2025 strain-specific systematic review (32 articles, 10 strains) confirmed B. longum 35624 among strains with meta-analytic IBS efficacy. A meta-analysis of 23 probiotic trials (1,404 IBS patients) found global IBS improvement (RR 0.77) and abdominal pain reduction (RR 0.78) with Bifidobacterium-containing probiotics. British Society of Gastroenterology recognizes Bifidobacterium for IBS symptom relief.

Bifidobacterium animalis subspecies lactis, particularly strains BB-12 and HN019, has clinical evidence for IBS-related bowel dysfunction. BB-12 is specifically recommended for IBS-C; HN019 is shown in RCTs to increase colonic transit speed and stool frequency. Both strains are included in evidence-based IBS probiotic guidance for constipation-predominant subtypes.

B. bifidum MIMBb75 is among the best-evidenced single-strain probiotics for IBS. A double-blind, placebo-controlled RCT in 122 IBS patients showed it significantly reduced global IBS symptom scores, abdominal pain, bloating, and improved quality of life versus placebo. A subsequent larger Lancet Gastroenterology trial (443 patients) confirmed benefit even with heat-inactivated bacteria. Overall evidence rates at SORT C due to mixed meta-analytic results when pooling all Bifidobacterium species.

Bifidobacterium breve has been studied in IBS and functional GI disorders, primarily in multi-strain probiotic formulations demonstrating clinical benefit. A meta-analysis of 23 probiotic trials in 1,404 IBS patients showing global IBS improvement and abdominal pain reduction included Bifidobacterium-containing preparations incorporating B. breve. Standalone IBS RCT evidence is more limited than for B. longum 35624.

Bifidobacterium infantis 35624 (reclassified as B. longum 35624) is the most studied individual probiotic strain specifically for IBS. A 2025 strain-specific meta-analysis (32 articles) confirmed its efficacy for key IBS symptoms. An 8-week RCT with 75 participants demonstrated significant reductions in pain, discomfort, bloating, and constipation. A landmark RCT confirmed it normalizes the gut IL-10/IL-12 cytokine ratio—a unique mechanistic marker for IBS immune dysregulation.

Multiple RCTs have tested B. lactis strains in IBS patients. B. lactis BI040 in a 12-week RCT reduced pain frequency and intensity, while B. lactis UABla-12 improved abdominal pain severity. Meta-analyses of Bifidobacterium strains in IBS show limited but significant benefits over placebo, primarily for pain and global symptoms.

Bifidobacterium longum 35624 (formerly B. infantis 35624) has the strongest meta-analytic evidence among Bifidobacterium species for IBS, confirmed in a 2025 systematic review of 32 RCTs. Multiple trials document significant improvements in abdominal pain, bloating, and bowel function. It is one of five probiotic strains with meta-analytic IBS efficacy in current systematic reviews alongside L. rhamnosus GG and L. plantarum 299v.

Bile acid malabsorption is an increasingly recognized subtype mechanism within IBS, particularly IBS-D. Up to one-third of IBS-D patients have measurable bile acid malabsorption on objective testing (SeHCAT or serum C4). IBS-C patients show opposite findings—reduced fecal bile acid excretion and slower transit. Bile acid profile alterations are now incorporated into mechanistic models of IBS pathophysiology.

A subset of diarrhea-predominant IBS (D-IBS) patients has underlying exocrine pancreatic insufficiency. A clinical study (Clinical Gastroenterology and Hepatology, 2009) found 6.1% of 314 D-IBS patients had EPI, and those receiving pancreatic enzyme therapy showed significant improvements in stool frequency, consistency, and abdominal pain versus those without EPI. A pilot RCT of pancrealipase for postprandial IBS-D has also been published. The evidence pertains to a specific EPI-positive D-IBS subgroup, not IBS broadly.

Butyrate supplementation has demonstrated symptomatic benefit in IBS across small clinical trials, reducing abdominal pain, urgency, and bloating. A 2025 RCT of calcium butyrate in pediatric IBS (n=51) showed treatment success in 73% vs. 3.8% placebo. A referenced tributyrin-containing product (ButyraGen) trial also noted belly pain reduction. Most IBS evidence uses butyrate salts; tributyrin-specific human IBS RCTs are very limited.

Clinical evidence supports sodium butyrate supplementation for IBS symptom relief. Placebo-controlled studies show significant reductions in abdominal pain, bloating, and improvements in gut permeability. Butyrate regulates colonocyte function, gut motility, and local immune responses relevant to IBS pathophysiology.

Fermented cabbage (sauerkraut, kimchi) has been tested in IBS patients and shown to significantly reduce symptom severity. A 2018 clinical pilot RCT found both pasteurized and unpasteurized sauerkraut improved IBS symptoms, with unpasteurized also altering gut microbiota. A 2022 clinical study showed 210 g/day kimchi for 12 weeks improved defecation patterns in IBS.

IBS patients have markedly increased TRPV1-expressing sensory fiber density in the colon correlating with abdominal pain severity. Repeated capsaicin stimulation via dietary intake or supplementation desensitizes these fibers, and evolving clinical evidence supports the therapeutic role of capsaicin-mediated TRPV1 desensitization in IBS.

Caraway oil applied topically to the abdomen has been tested in a randomized controlled cross-over trial for IBS, with patients reporting the highest subjective benefit versus controls. The combination of caraway oil and peppermint oil (Menthacarin) has been evaluated in clinical trials for functional dyspepsia with IBS overlap, showing significant symptom reduction. Caraway's antispasmodic action on intestinal smooth muscle is considered the primary mechanism.

Cellulase is an ingredient in multi-enzyme digestive blends studied in IBS populations. The product Biointol—containing cellulase among several enzymes—was tested in an IBS clinical study and showed improvement in bloating, flatulence, and abdominal pain, though effects on other IBS symptoms were modest. Mechanistically, cellulase may reduce fermentable substrate reaching the colon, thereby decreasing gas production that drives IBS symptoms.

Chicory inulin has been evaluated in IBS patients with mixed results: some trials show benefit for constipation-predominant IBS (IBS-C) through improved stool frequency and microbiota modulation, while others at doses of 6–20 g/day show no improvement in global symptoms. Bifidobacteria enrichment by ITF may support IBS-C management.

A small open-label study assessed chlorella in IBS patients and found improvements in abdominal pain and bloating, though it lacked a placebo control. The evidence is preliminary and based on limited clinical data.

An RCT in 87 diarrhea-predominant IBS patients found that daily pectin significantly reduced symptoms, improved stool consistency, and enhanced quality of life versus placebo. Pectin acted as a prebiotic, boosting bifidobacteria and normalizing the IL-10/IL-12 inflammatory cytokine ratio. It is particularly studied in IBS-D (diarrhea-predominant subtype).

Bovine colostrum reduces intestinal permeability and inflammation—two mechanisms implicated in IBS pathophysiology. Animal and human data show BC preserves epithelial integrity and reduces inflammatory markers relevant to IBS. Its modulation of gut microbiota and mucosal immunity provides additional mechanistic support.

Berberine from Coptis chinensis has been studied in animal models of IBS, showing reduction of visceral hypersensitivity and gut dysbiosis. A clinical RCT of berberine in IBS-D patients showed significant improvements in stool frequency, urgency, and abdominal pain. Mechanistic links involve gut microbiota and spinal pain signaling.

A clinical pilot study in 57 IBS patients found cumin essential oil (20 drops/day for 4 weeks) significantly reduced abdominal pain, bloating, incomplete defecation, fecal urgency, and mucus in stool. Both diarrhea- and constipation-predominant IBS subtypes showed improvement.

Curcumin has demonstrated IBS symptom improvement across multiple clinical studies. A 2025 umbrella review (Nutr Rev, 175 RCTs) specifically identified curcumin as improving IBS symptom severity. A 2024 real-world clinical study (Nutrients, n=146) found 93.1% of IBS patients reported symptom improvement with berberine/curcumin combination. Curcumin modulates intestinal inflammation, serotonergic signaling, and gut barrier integrity—key IBS mechanisms.

IBS symptom profiles heavily overlap with histamine intolerance from DAO deficiency, and some evidence suggests elevated DAO activity levels in IBS patients correlate with disease severity. DAO deficiency is one mechanism linking histamine dysregulation to IBS-like presentations, and HIT is a recognized diagnostic confounder of IBS.

Digestive enzyme preparations including DPPIV-active peptidases have been trialed in populations that overlap substantially with IBS, particularly non-celiac gluten sensitivity (NCGS) patients who often meet IBS diagnostic criteria. A 2020 narrative review (PMC6910206) covers decades of randomized controlled trials for multi-enzyme blends targeting IBS-like post-prandial diarrhea and abdominal symptoms. A double-blind RCT (PMC4488801) confirmed that a large proportion of IBS patients show gluten sensitivity, the key substrate for DPPIV activity. The contribution of DPPIV specifically versus other enzymes in blends is not isolated.

Two small clinical studies in IBS adults found significant improvement in symptoms with asafoetida supplementation; however, a third study found no effect (Healthline). The PMC6129344 RCT in functional dyspepsia—which overlaps with IBS symptomatology—strongly supports gastrointestinal smooth-muscle modulation. Asafoetida is a primary Ayurvedic IBS remedy.

Ground flaxseed has been studied for IBS, with evidence suggesting benefits for constipation-predominant IBS including relief of constipation, reduced bloating, and improved bowel habits. A 2004 study found ground flaxseed more effective than psyllium for IBS-C.

Fructooligosaccharides (FOS) are prebiotic fibers that stimulate beneficial gut bacteria (Bifidobacterium, Lactobacillus), modulating the dysbiotic microbiome central to IBS. Synbiotic combinations (probiotic plus FOS prebiotic) have demonstrated IBS symptom improvements in clinical trials. FOS are included in evidence-based IBS management as prebiotic support, though high doses may worsen FODMAP-sensitive IBS.

Digestive enzyme blends containing fungal protease have been employed as adjunct therapies in functional GI disorders including IBS, with clinical evidence from dyspepsia trials supporting symptom reduction. Protease activity may help reduce the protein fermentation load reaching the colon, which can contribute to IBS symptoms. Evidence specific to IBS vs. functional dyspepsia remains limited.

Galactooligosaccharides (GOS) have IBS-specific RCT evidence. A double-blind placebo-controlled RCT (Silk et al., Aliment Pharmacol Ther 2009, n=44 IBS patients) found 3.5 g/day GOS significantly improved stool consistency, bloating, and anxiety scores in IBS patients alongside beneficial microbiota changes. Unlike higher-FODMAP prebiotics, low-dose GOS appears tolerable and directly beneficial in IBS.

The relationship between garbanzo beans and IBS is bidirectional: chickpea fiber can ease constipation-predominant IBS symptoms and reduce gut inflammation, but their high FODMAP content (fermentable oligosaccharides, particularly galacto-oligosaccharides) can trigger bloating, gas, and pain in sensitive IBS individuals. A 2024 Heliyon review (PMC11532829) documented chickpea fiber as reducing IBS symptoms via anti-inflammatory mechanisms.

Ginger has clinically documented antispasmodic, prokinetic, and anti-nausea properties directly relevant to IBS symptoms via 5-HT3 receptor antagonism and prostaglandin modulation. Evidence-based herbal medicine reviews cite ginger for IBS-related bloating, cramping, and nausea with moderate clinical evidence. Traditional use for GI complaints spans Ayurvedic, Chinese, and European medicine for over 2,000 years.

Rare deleterious variants in the MGAM gene have been identified as candidate contributors to IBS susceptibility, linking glucoamylase deficiency to IBS-like carbohydrate malabsorption symptoms. Multi-enzyme blends including glucoamylase have improved GI symptoms in IBS patients in clinical trials.

Clinical trials have investigated glucomannan for IBS-related symptoms including abdominal pain, bloating, constipation, and diarrhea. A double-blind RCT (Horvath et al. 2013, World J Gastroenterol, n=children with abdominal pain-related FGIDs) assessed glucomannan at 2.52 g/day vs. placebo, evaluating pain and bowel outcomes. A study by Al-Ghazzewi explored konjac glucomannan hydrolysates in IBD-spectrum patients including IBS.

Multi-enzyme blends including hemicellulase have been included in small human studies reporting modest improvements in IBS-related symptoms such as bloating, gas, and altered stool consistency. Hemicellulase reduces hemicellulosic fermentation substrate reaching the colon, directly addressing a driver of gas-related IBS symptoms. Direct RCTs isolating hemicellulase in IBS are absent; evidence comes from multi-enzyme formulation studies.

SBI (serum-derived bovine IgG) has clinical evidence in diarrhea-predominant IBS (IBS-D). Multiple studies, including a pilot RCT and retrospective chart reviews, demonstrate significant reductions in abdominal pain, loose stools, bloating, and urgency. Mechanistic studies from Mayo Clinic indicate SBI improves bowel function and alters duodenal microbiota composition.

Inulin is a prebiotic fiber studied in IBS for gut microbiome modulation. Low-dose inulin in synbiotic formulations with probiotics has demonstrated IBS symptom improvements in clinical trials. A systematic review of synbiotics and fiber for functional bowel disorders recognizes inulin-containing synbiotics as beneficial. Note: inulin is a FODMAP and at higher doses may worsen symptoms in FODMAP-sensitive IBS patients.

A rat model of IBS demonstrated that IMO reduced visceral hypersensitivity and repaired ileal epithelial ultrastructural damage. IMO is classified as low FODMAP, making it generally tolerated by IBS patients. Human clinical trial evidence in IBS populations is limited.

L-glutamine has strong RCT evidence for post-infectious diarrhea-predominant IBS. A landmark RCT (Zhou et al., Gut 2019, n=106) showed 79.6% of IBS-D patients receiving 15 g/day achieved significant symptom reduction versus 5.8% placebo. A second RCT (Front Nutr 2021, n=50) found 88% responder rate adding glutamine to a low-FODMAP diet. Glutamine restores intestinal barrier tight junctions, a key mechanism in IBS-D with documented hyperpermeability.

Lactose malabsorption and IBS are considered independent conditions, yet many IBS patients report milk intolerance and symptom overlap. When dairy triggers IBS-like symptoms in confirmed lactose malabsorbers, lactase supplementation can improve dairy tolerance. However, a double-blind crossover trial and a PMC review found no conclusive evidence that lactase supplementation broadly benefits IBS as a functional disorder independent of confirmed lactose malabsorption.

Lactobacillus species as a genus have the most extensive probiotic evidence base for IBS. Meta-analyses including 23 trials and over 1,400 patients demonstrate global IBS symptom improvement and abdominal pain reduction. A 2025 strain-specific review confirmed multiple Lactobacillus strains in meta-analytic efficacy for IBS. British Society of Gastroenterology guidelines specifically recognize Lactobacillus for IBS probiotic treatment.

Lactobacillus acidophilus is among the most commonly studied Lactobacillus strains in IBS clinical trials. Multiple RCTs have included L. acidophilus for IBS, demonstrating improvements in abdominal pain, bloating, and bowel habits. A meta-analysis of 23 probiotic RCTs in 1,404 IBS patients showing global symptom improvement included L. acidophilus-containing preparations.

A multicenter randomized placebo-controlled trial using a combination of L. acidophilus and L. bulgaricus (Rome III criteria) found probiotics effective in improving IBS symptomatology. The VSL#3 formulation, which includes L. bulgaricus, also showed significant improvement in constipation-subtype IBS. Evidence is for multi-strain formulations containing L. bulgaricus rather than for L. bulgaricus as a sole agent.

Lactobacillus casei has been evaluated in clinical trials for IBS with mixed evidence depending on strain. A 2025 strain-specific meta-analysis found L. casei Shirota did not demonstrate meta-analytic IBS efficacy despite some positive individual trials. The broader genus shows benefit and L. casei is included in British Society of Gastroenterology recognition of Lactobacillus for IBS.

Multiple RCTs demonstrate efficacy of L. gasseri in IBS. L. gasseri BNR17 reduced diarrhea symptoms, abdominal pain, and distension in a double-blind RCT in diarrhea-predominant IBS. L. gasseri LA806 achieved a 49.1% reduction in global IBS symptom intensity in a multicenter study. L. gasseri has also shown benefits in IBS-related constipation.

Lactobacillus paracasei has been studied in IBS and functional GI disorders within multi-strain probiotic formulas showing clinical benefit. Strain combinations including L. paracasei HEAL9 with L. plantarum 8700:2 have demonstrated efficacy in GI symptom reduction in RCTs. It is included in evidence-based probiotic guidance for functional bowel disorders.

Lactobacillus plantarum, particularly strain 299v (DSM 9843), has meta-analytic evidence for IBS symptom improvement confirmed in a 2025 strain-specific systematic review of 32 RCTs. A 4-week RCT in 60 IBS patients showed decreased flatulence, pain, and improved bowel habits. It is one of five probiotic strains with confirmed meta-analytic IBS efficacy alongside B. longum 35624 and L. rhamnosus GG.

Lactobacillus reuteri has clinical evidence in functional GI disorders relevant to IBS. Specific strains (DSM 17938) have documented benefits for GI motility, bowel habits, and abdominal symptoms in clinical trials. It is included in evidence-based probiotic guidance for functional bowel disorders and studied in adults with IBS-related GI symptoms.

Lactobacillus rhamnosus GG has meta-analytic evidence for IBS efficacy confirmed in a 2025 strain-specific systematic review (32 RCTs, 10 strains). It is specifically named as one of the best-evidenced individual probiotic strains for IBS. A 2017 systematic review specifically identified L. rhamnosus as among the probiotics effective for ameliorating IBS symptoms.

Lactobacillus salivarius has been evaluated in IBS clinical trials, with at least one RCT demonstrating improvement in global IBS symptoms. It is included in meta-analyses of probiotic trials for IBS demonstrating overall benefit for abdominal pain and global symptoms. Evidence is modest but derives from peer-reviewed RCT data.

GABA-producing L. lactis strains significantly ameliorated IBS-related outcomes in a validated mouse model, including visceral hypersensitivity, intestinal barrier dysfunction, and neurobehavioral abnormalities in a dose-dependent manner. Recombinant IL-10-secreting L. lactis also reduced gut hyperpermeability and serotonin dysregulation in a chronic IBS-like rodent model. Clinical evidence is preclinical-dominant, but mechanistically well-grounded.

Fecal lactoferrin serves as a key biomarker distinguishing IBD (elevated levels) from IBS (normal levels), which has significant diagnostic utility. IBS is characterized by normal fecal lactoferrin, supporting its differential diagnostic role. Therapeutic use of lactoferrin in IBS specifically has limited published trial data.

A clinical study in gastritis patients showed Lion's Mane reduced GI inflammation and modulated gut microbiota, with researchers suggesting potential in IBS. Animal models show improvement in gut barrier integrity and inflammatory signaling relevant to IBS pathophysiology. Dedicated human IBS trials are absent.

There is limited but emerging clinical evidence for digestive enzyme blends containing lipase in IBS, particularly overlapping with IBD. A controlled study in 43 IBD-IBS overlap patients found that a combination supplement including digestive enzymes reduced bloating, flatulence, and abdominal pain. Evidence specific to lipase as an isolated agent in IBS is not established.

Melatonin has meta-analytic evidence for IBS. A 2022 meta-analysis (4 RCTs, 115 participants) found exogenous melatonin significantly improved overall IBS severity versus placebo (Hedges' g=0.746, p<0.001), IBS pain severity (p<0.001), and quality of life (p=0.007). A 2023 RCT in 136 ROME IV–diagnosed IBS patients found significant improvement in IBS score, GI symptoms, and quality of life with 6 mg melatonin daily for 8 weeks.

Enteric-coated peppermint oil (delivering menthol to the intestine) is one of the best-evidenced herbal treatments for IBS, with multiple RCTs and meta-analyses demonstrating significant superiority over placebo for both global symptom improvement and abdominal pain.

Enteric-coated peppermint oil is the most rigorously studied botanical agent for IBS, consistently reducing abdominal pain and global symptom scores versus placebo. Multiple systematic reviews and meta-analyses of RCTs confirm efficacy. European, Canadian, and Japanese clinical guidelines recommend it. The American College of Gastroenterology (2021) also endorsed it.

NAG supports the intestinal mucosal barrier and selectively promotes beneficial gut bacteria including Bifidobacterium species, which are commonly depleted in IBS patients. Clinical evidence is indirect—primarily from IBD studies where IBS-like symptoms improved—but NAG's mucin-building and microbiome-modulating effects are mechanistically relevant to IBS.

Oat β-glucan's viscous soluble fiber properties are associated with improved IBS symptoms, particularly reduction of intestinal permeability and abdominal pain. Viscous soluble fibers including β-glucan show broader symptom relief across IBS subtypes than insoluble fibers.

Berberine from Oregon grape has been evaluated in human IBS studies showing reductions in pain, diarrhea frequency, and IBS symptoms. Animal studies demonstrate berberine alleviates visceral hypersensitivity by modulating the gut microbiome and suppressing spinal microglial activation. Evidence is primarily for isolated berberine; Oregon grape whole-root IBS trials are not published.

There is substantial evidence that bile acid dysregulation — both excess (in IBS-D) and deficiency (in IBS-C) — contributes to IBS symptom generation. Approximately 25–33% of IBS-D patients have underlying bile acid malabsorption. Ox bile supplementation is not a recognized IBS treatment and has not been tested in IBS-specific RCTs; the relationship is mechanistic, established through studies of bile acid profiles and receptor signaling in IBS subgroups.

A PMC-indexed study demonstrated that ethanolic leaf extract of P. foetida significantly ameliorated experimentally induced colitis in albino rats, reducing disease activity index and oxidative stress markers. This provides direct preclinical evidence relevant to inflammatory bowel conditions including IBS.

Two clinical studies in IBS patients reported improvements in constipation, bloating, flatulence, and painful bowel movements with papaya enzyme. The Caricol® RCT (Muss et al., 2013; PMID 23524622) specifically recruited subjects with IBS-type symptoms and found significant improvements at 40 days. The evidence base, while genuine, is small-scale and uses papaya preparations rather than purified papain.

Clinical evidence from two trials in over 150 patients documents improvement in IBS symptoms — including constipation, bloating, and painful bowel movements — following papaya enzyme preparation (Caricol®) supplementation. Papaya is also low-FODMAP, which reduces the likelihood of triggering IBS symptoms compared to high-FODMAP foods.

A controlled clinical trial demonstrated that pectin supplementation significantly reduces IBS-D symptoms including abdominal pain, diarrhea, and bloating. Pectin's prebiotic and gut-modulating properties provide a mechanistic rationale for benefit across IBS subtypes.

Peppermint oil is the most robustly evidenced botanical for IBS, supported by multiple meta-analyses of RCTs. A meta-analysis of 7 RCTs (634 patients) found peppermint oil superior to placebo (RR 0.54; 95% CI 0.39–0.76) for global IBS symptoms. A 2022 systematic review (Aliment Pharmacol Ther) confirmed efficacy for abdominal pain reduction. It is the only plant-based therapy consistently acknowledged across international adult and pediatric IBS guidelines.

Psyllium (Plantago ovata husk) is the only fiber supplement specifically recommended by the American College of Gastroenterology for IBS. Multiple RCTs demonstrate significant improvement in global IBS symptoms, stool consistency, and abdominal discomfort. It is well-tolerated in both constipation-predominant and diarrhea-predominant IBS.

Psyllium (Plantago ovata husk) is the only fiber recommended by the American College of Gastroenterology for irritable bowel syndrome. It is the sole fiber meeting evidence criteria for IBS management. Multiple clinical trials support its use for IBS-related constipation, diarrhea, and abdominal discomfort via its gel-forming, microbiota-modulating fiber action.

IBS patients, particularly the diarrhea-predominant subtype, show altered SCFA profiles including propionate. A 2025 double-blind RCT found that probiotic-induced increases in propionate (alongside acetate and butyrate) correlated with reduced intestinal permeability, upregulated tight junction proteins, and decreased symptom severity across IBS subtypes. Low propionate availability is implicated in impaired gut barrier function and motility dysregulation in IBS.

Psyllium is a soluble fiber with among the strongest evidence for IBS. Meta-analyses including over 1,400 IBS patients show improvement in global symptoms (RR 0.77) and abdominal pain (RR 0.78). A 2025 umbrella review (Nutr Rev, 175 RCTs) confirmed soluble fiber improved IBS symptoms. British Society of Gastroenterology and American College of Gastroenterology guidelines recommend soluble fiber as first-line for IBS.

Saccharomyces boulardii is among probiotics specifically named in a 2017 systematic review as effective for ameliorating IBS symptoms. It is the primary probiotic recommendation for IBS-D in some clinical guidelines. A 2025 strain-specific meta-analysis found conflicting results for CNCM I-745 specifically, but multiple individual trials support its use, particularly for diarrhea-predominant IBS.

Preliminary research has identified Massa Medicata Fermentata as capable of relieving visceral hypersensitivity symptoms including abdominal tension, abdominal pain, and diarrhea in IBS with diarrhea (IBS-D). Evidence is preclinical and based on combination formulas; direct human RCT data for shen-chu alone in IBS are absent.

The strongest clinical evidence for slippery elm is in IBS. A 2010 published pilot study (Hawrelak & Myers) using two slippery elm-containing formulas in 31 IBS patients found significant improvements in bowel movement frequency, stool consistency, abdominal pain, bloating, and global symptom severity—particularly in constipation-predominant IBS. MSKCC and Memorial Sloan Kettering both cite this as supporting evidence.

Spearmint's antispasmodic constituent carvone relaxes intestinal smooth muscle and has been combined with peppermint oil to reduce IBS symptoms in human studies. A 2014 combination study found IBS symptom relief. The plant has an extensive traditional record for gastrointestinal spasm disorders.

One rigorous randomized, double-blind, placebo-controlled trial (n=70, 12 weeks, Mayo Clinic) found SJW was no more effective — and actually inferior to placebo — for IBS symptom scores. Though antidepressants are often used for IBS and SJW has serotonergic activity, clinical evidence does not support its use for IBS.

S. thermophilus has been studied as part of multi-strain probiotic preparations for IBS, with VSL#3 showing superiority over placebo in reducing abdominal pain, discomfort, and bloating in children with IBS in a randomized trial. An RCT also showed that S. thermophilus-containing fermented milk improved global IBS symptom scores and small intestinal permeability.

Multiple peer-reviewed genetic studies have identified sucrase-isomaltase (SI) gene variants as risk factors for IBS, particularly IBS with diarrhea. Partial or hypomorphic SI deficiency produces symptoms—diarrhea, bloating, abdominal pain—that closely overlap with and are often misdiagnosed as IBS. A 2018 landmark study in Gut demonstrated that functional SI variants significantly increase IBS susceptibility in a large multi-center cohort.

Clinical trials and a meta-analysis of RCTs indicate curcumin may improve IBS symptoms, likely via mucosal anti-inflammatory and gut microbiome-modulating effects. A PMC meta-analysis identified 3 eligible RCTs for inclusion with positive directional findings. Evidence is promising but limited in volume.

Vitamin D3 has IBS-specific RCT and meta-analytic evidence. A 2025 umbrella review (Nutr Rev, 175 RCTs) identified vitamin D3 as improving IBS symptom severity. An RCT in 74 IBS-D patients with vitamin D deficiency found significant IBS symptom severity and IL-6 reduction with 50,000 IU/week for 9 weeks versus placebo. Vitamin D deficiency is disproportionately prevalent in IBS patients.

A clinical trial in 60 IBS patients using an herbal combination including yarrow demonstrated reduced stomach pain and bloating. Yarrow's spasmolytic, prokinetic, and anti-inflammatory properties provide mechanistic support, and it is traditionally indicated for spasmodic gut conditions.

Saccharomyces boulardii has been tested in multiple RCTs for irritable bowel syndrome, predominantly the diarrhea-predominant subtype (IBS-D). A multicenter RCT found 15.4% improvement in IBS-specific quality of life vs. 7.0% for placebo. Cytokine modulation (reducing IL-8 and TNF-α, raising IL-10) has been demonstrated as a plausible mechanism.

Agrimony is listed among traditional remedies for irritable bowel syndrome in several herbal references and is cited for IBS use by RxList and WebMD, drawing on its astringent and anti-inflammatory actions. No clinical trials specifically in IBS have been conducted; the evidence base is entirely traditional.

Asparagus inulin-type FOS have prebiotic properties that may modulate gut microbiota relevant to IBS. A. racemosus is classified as carminative and stomachic in traditional Ayurvedic references and documented for dyspepsia. The demulcent and anti-inflammatory properties of asparagus are relevant to IBS. No human clinical trial evidence for IBS specifically exists.

Bilberry has a documented European traditional use for gut inflammation, diarrhea, and gastrointestinal upset that encompasses symptoms overlapping with IBS. The tannin content is considered relevant to bowel-regulating effects. No specific controlled clinical trials in IBS populations have been identified.

Boswellia serrata has traditional Ayurvedic use for GI inflammatory complaints and clinical evidence from IBD trials (comparable to mesalazine for ulcerative colitis) supporting GI anti-inflammatory application. For IBS, evidence is primarily mechanistic (5-LOX inhibition, mast cell stabilization relevant to IBS pathophysiology) and from traditional Ayurvedic use, with extrapolation from IBD trials. IBS-specific standalone RCTs are limited.

Caprylic acid's antifungal and antimicrobial properties lead to its use by integrative practitioners for IBS cases believed to involve Candida overgrowth or dysbiosis. Caprylic acid is depleted in IBD stool metabolomics. No RCT has directly tested caprylic acid for IBS symptom relief; the clinical use is based on the Candida–IBS hypothesis and practitioner experience.

Chamomile (Matricaria chamomilla) is a classical antispasmodic and carminative herb used in traditional European, Middle Eastern, and Ayurvedic medicine for IBS-like symptoms including cramping, bloating, and diarrhea. It is a component of the clinically studied multi-herb formula Iberogast (STW-5). Dedicated IBS-specific RCTs for chamomile alone are limited, but its inclusion in evidence-based combination formulas and long-standing traditional use support its application for IBS.

Chen Pi is traditionally prescribed in TCM for IBS-pattern presentations including alternating bloating, diarrhoea, and abdominal discomfort related to spleen-stomach Qi dysfunction. It is a component of multiple classical formulas used for IBS-equivalent conditions.

Chickweed is included in herbal practice for IBS, where its demulcent, anti-inflammatory, and mild laxative properties are considered beneficial for irritated bowel. Herbal Reality specifically lists IBS among digestive tract indications. No clinical trials exist.

Coleus forskohlii has traditional use for irritable bowel syndrome (spastic colon) based on its documented smooth-muscle-relaxing activity. cAMP elevation relaxes gut smooth muscle, providing pharmacological rationale. No clinical trials for IBS have been published.

Wild yam is a well-established antispasmodic herb used traditionally for irritable bowel syndrome, intestinal colic, and bowel cramping. Its smooth muscle relaxant properties provide the pharmacological rationale. Preclinical evidence supports anti-inflammatory and antioxidant intestinal effects, but no human IBS trials exist.

Fennel (Foeniculum vulgare) is a traditional carminative herb used for centuries for IBS-associated bloating, flatulence, and abdominal cramps in European, Ayurvedic, and Chinese herbal medicine. Its volatile oil, particularly anethole, has demonstrated antispasmodic activity. Fennel is a component of combination IBS herbal formulas used clinically, though standalone large-scale RCTs in IBS are limited.

Forskolin's documented spasmolytic action on intestinal smooth muscle underlies its Ayurvedic use for intestinal colic and spastic conditions including IBS. The EBSCO Research Starters explicitly list IBS (spastic colon) among proposed uses. No human clinical trials for IBS have been published.

Fu Ling is used in TCM for patterns corresponding to IBS symptoms — loose stools, diarrhea, abdominal bloating, and digestive weakness due to Spleen deficiency. Classical formulas like Si Jun Zi Tang and Shen Ling Bai Zhu San (specifically for Spleen deficiency with diarrhea) include Fu Ling as a core ingredient.

Traditional Ayurvedic medicine—in which amla is a core component of Triphala—has documented its use for IBS-like digestive disorders including spastic bowel, alternating constipation/diarrhea, and abdominal bloating for millennia. Modern mechanistic data support gut motility and anti-inflammatory effects.

Kutaj is listed in Ayurvedic and modern herbal practice for irritable bowel syndrome due to its dual modulatory effect on gut motility via histaminergic and calcium-channel pathways. The pharmacological basis for this was investigated by Gilani et al. (2010). Clinical IBS-specific trials are lacking.

Hydrangea is listed in TCM and Western herbal references as a remedy for inflammatory bowel syndrome (IBS), attributed to its anti-inflammatory and potentially antispasmodic properties. This is a documented but minority traditional use. No clinical or laboratory research has specifically evaluated hydrangea for IBS.

Bael has been referenced in traditional medicine and formulation patents for the management of irritable bowel syndrome (IBS) due to its dual ability to regulate bowel motility, reduce colonic inflammation, and modulate gut immune responses. Its traditional use for GI complaints overlaps with classical IBS symptomatology.

Indian Frankincense is traditionally used in Ayurvedic medicine for bowel complaints including diarrhoea and abdominal discomfort, conditions overlapping with IBS symptomatology. Its anti-inflammatory and gut mucosal protective properties provide a plausible rationale, and it is listed in traditional texts for bowel disease, but no specific human clinical trials in diagnosed IBS have been identified.

Lemon balm (Melissa officinalis) is a traditional antispasmodic and anxiolytic herb used in European herbal medicine for IBS, particularly for stress-related and mixed-type IBS with gut-brain axis involvement. It is a component of the clinically studied Iberogast (STW-5) formula. Commission E and ESCOP support its use for nervous agitation and associated GI spasms, directly relevant to IBS.

Licorice root (Glycyrrhiza glabra) has been used in traditional Ayurvedic, Chinese, and European herbal medicine for IBS, particularly for gut inflammation, spasm, and IBS-C. DGL (deglycyrrhizinated licorice) is used clinically as a mucoprotective agent. A clinical study showed significant IBS symptom improvement when combined with slippery elm. Iberogast, a multi-herb formula with RCT evidence in IBS, contains licorice root.

Marshmallow root (Althaea officinalis) contains mucilage that coats the GI mucosa, traditionally used in European herbal medicine for IBS-related gut irritation, cramping, and diarrhea. Commission E approves marshmallow root for irritation of the oral and pharyngeal mucosa; ESCOP supports its use for GI mucosal irritation. Clinical trials specific to IBS are limited but traditional and mechanistic evidence is well established.

Mastic gum (Pistacia lentiscus resin) has a centuries-long traditional use in Mediterranean medicine for IBS-like GI complaints, and clinical evidence for functional dyspepsia with substantial IBS symptom overlap. It is cited in GI clinical literature for IBS-associated symptoms. Anti-inflammatory and antimicrobial mechanisms are well characterized; IBS-specific large standalone RCTs remain limited.

Oregano is commonly used in functional medicine protocols for IBS symptom relief, leveraging its antimicrobial activity against bacterial overgrowth (SIBO) frequently co-occurring with IBS. However, no human RCTs specifically evaluating oregano oil for IBS diagnosis have been published, and the evidence base for this specific indication remains in vitro and anecdotal. It qualifies as traditional given documented carminative folk use.

PABA is occasionally used by IBS sufferers for gastrointestinal symptoms. This use is documented in reference sources including Wikipedia's entry on 4-aminobenzoic acid, which notes pill-form use among IBS patients. No clinical trials specifically investigating PABA for IBS have been identified.

IBS-type presentations of abdominal pain with diarrhea or spasm are addressed in TCM by siler root through its wind-expelling and intestine-harmonizing properties. Classical TCM indications for SD include abdominal pain and diarrhea from wind invading the intestines—descriptions that overlap with IBS symptomatology. No modern clinical studies specifically for IBS exist.

S. baicalensis exerts anti-spasmodic effects on intestinal smooth muscle (wogonin), anti-inflammatory effects (baicalin via COX-2/PGE2), and gut microbiota modulation, all relevant to IBS pathophysiology. Preclinical data for diarrhea-predominant IBS are promising; human IBS trials specifically with skullcap are absent.

Slippery elm (Ulmus rubra) bark contains mucilage that coats and soothes the intestinal lining, used traditionally for IBS in North American herbal medicine. A mixture of slippery elm bark, lactulose, oat bran, and licorice root significantly improved bowel habit and IBS symptoms in patients with constipation-predominant IBS. It is recommended in evidence-informed herbal practice for IBS-M and IBS-C.

Triphala is a classical Ayurvedic tri-herbal formulation (Emblica officinalis, Terminalia bellerica, Terminalia chebula) used for over 1,000 years for IBS-like symptoms including constipation, bloating, and abdominal cramps. Clinical studies demonstrate benefit for chronic constipation directly relevant to IBS-C. Ayurvedic pharmacopeias classify it as a primary GI therapeutic for functional bowel disorders.

Wheatgrass is listed in traditional naturopathic literature as a remedy for irritable bowel syndrome. The documented digestive enzymes, anti-inflammatory chlorophyll, and indirect evidence from the UC RCT provide mechanistic and contextual support. No RCT exists for IBS specifically.

White oak bark is used in traditional herbalism for irritable bowel syndrome (IBS), primarily for diarrhea-predominant forms. The astringent tannins tone intestinal tissue and reduce secretions. Germany's Commission E approval for diarrhea provides indirect support for IBS-D symptom management. No clinical trials for IBS have been conducted.

Wild yam is traditionally used in Western herbal medicine for irritable bowel syndrome, valued for its antispasmodic and mild anti-inflammatory effects on intestinal smooth muscle. Multiple herbal monographs and herbalism texts list IBS among its indications. No clinical trials in IBS patients have been conducted.